Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Ischemix","sponsor":"US Department of Defense","pharmaFlowCategory":"D","amount":"$2.9 million","upfrontCash":"Undisclosed","newsHeadline":"Ischemix Receives US DoD Funding of $2.9M to Conduct Phase 1 Study of Drug Candidate to Treat Traumatic Brain Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Ischemix

    Menu

    Ischemix

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Ischemix

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ischemix Receives US DoD Funding of $2.9M to Conduct Phase 1 Study of Drug Candidate to Treat Traumatic Brain Injury

              Details:

              CMX-2043, a multi-modal cytoprotective compound based on a naturally-occurring molecule present in the human body, has previously demonstrated safety and efficacy in preclinical models of TBI.

              Lead Product(s): CMX-2043

              Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: CMX-2043

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: US Department of Defense

              Deal Size: $2.9 million Upfront Cash: Undisclosed

              Deal Type: Funding July 07, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY